Neuroaxonal and Glial Markers in Patients of the Same Age With Multiple Sclerosis
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received July 21, 2022
- Accepted in final form November 1, 2022
- First Published December 21, 2022.
Author Disclosures
- Floor C. Loonstra, MD,
- Lodewijk R.J. de Ruiter, MD,
- Marleen J.A. Koel-Simmelink, PhD,
- Menno M. Schoonheim, PhD,
- Eva M.M. Strijbis, MD, PhD,
- Bastiaan Moraal, MD, PhD,
- Frederik Barkhof, MD, PhD,
- Bernard M.J. Uitdehaag, MD, PhD,
- Charlotte Teunissen, PhD and
- Joep Killestein, MD, PhD
- Floor C. Loonstra, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Lodewijk R.J. de Ruiter, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Marleen J.A. Koel-Simmelink, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Menno M. Schoonheim, PhD,
None
NONE
None
Neurology, editorial board member, 2022-Frontiers in Neurology, Associate Editor, 2021-
NONE
NONE
NONE
NONE
Speaker honoraria from Sanofi-Genzyme
NONE
NONE
Research support from Atara Biotherapeutics, Biogen, BMS/Celgene, EIP Pharma, Sanofi-Genzyme, MedDay and Merck.
NONE
NONE
ARSEP, MSIF, Amsterdam Neuroscience, Dutch MS Research Foundation, MAGNIMS
NONE
NONE
NONE
NONE
NONE
NONE
- Eva M.M. Strijbis, MD, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Bastiaan Moraal, MD, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
B. Moraal has received funding from the Dutch MS Research Foundation and the Brain Foundation Netherlands for the Activity Study, projectnumber 20-1109 MS
NONE
NONE
NONE
NONE
NONE
NONE
- Frederik Barkhof, MD, PhD,
Biogen, Merck, Roche, Eisai, Merck, Prothena, Combinostics
NONE
None
Editorial board member for Radiology, Multiple Sclerosis Journal, Neuroradiology (section editor), Neurology
NONE
NONE
NONE
Novartis, Biogen, Roche, Janssen, IXICO
NONE
NONE
NONE
Image analysis in CONSONANCE study (Roche)
AMYPAD coordinator (IMI), NIHR-UCLH biomedical research centre
NONE
OCTOPUS study by the UK MS society
Founder and stock-owner of Queen Square Analytics LTD
NONE
NONE
NONE
NONE
NONE
- Bernard M.J. Uitdehaag, MD, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
Novartis, Merck Serono, Biogen Idec, TEVA, Sanofi Genzyme, Roche, and Immunic Therapeutics
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Charlotte Teunissen, PhD and
Roche. Novo Nordisk. Merck. Siemens.
NONE
Roche, Novo Nordisk, Grifols, payment to my institute.
CET serves on editorial boards of Medidact Neurologie/Springer, Alzheimer Research and Therapy, Neurology: Neuroimmunology & Neuroinflammation
NONE
NONE
NONE
NONE
NONE
CET has a collaboration contract with ADx Neurosciences, Quanterix and Eli Lilly, performed contract research or received grants from AC-Immune, Axon Neurosciences, BioConnect, Bioorchestra, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, Fujirebio, Grifols, Instant Nano Biosensors, Novo Nordisk, PeopleBio, Roche, Siemens, Toyama, Vivoryon.
NONE
NONE
Network, grant agreement No 860197 (MIRIADE), Innovative Medicines Initiatives 3TR (Horizon 2020, grant no 831434) EPND ( IMI 2 Joint Undertaking (JU), grant No. 101034344) and JPND (bPRIDE), National MS Society (Progressive MS alliance), Alzheimer Association, Health Holland, the Dutch Research Council (ZonMW), Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands. CT is recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106).
NONE
None
NONE
NONE
Technology of Amyblood test, contract with ADx Neurosciences, 2021.
NONE
NONE
NONE
- Joep Killestein, MD, PhD
Steering committees Roche and Biogen trials
NONE
Speaker honoraria Biogen, Novartis, TEVA, Merck, Roche
Former editor of the official scientific journal of the Dutch Society of Neurology, the Dutch Society of Neurosurgeons and the Society of Flemish Neurologists (Tijdschrift voor Neurologie en Neurochirurgie). Editorial board MS JournalEditorial board Neurology
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I have been involved in clinical trials of several companies that market drugs for MS. The past two years Biogen and Roche sponsored trials.
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- From the MS Center Amsterdam (F.C.L., L.R.J.R., E.M.M.S., B.M.J.U., J.K.), Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC Location VUmc, The Netherlands; Neurochemistry Laboratory (M.J.A.K.-S., C.T.), Clinical Chemistry, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC Location VUmc, The Netherlands; MS Center Amsterdam (M.M.S.), Anatomy and Neurosciences, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC Location VUmc, The Netherlands; MS Center Amsterdam (B.M., F.B.), Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC Location VUmc, The Netherlands; andQueen Square Institute of Neurology and Centre for Medical Image Computing (F.B.), University College London, United Kingdom.
- Correspondence
Dr. Loonstra f.loonstra{at}amsterdamumc.nl
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. David E. Vaillancourt and Dr. Shannon Y. Chiu
► Watch
Related Articles
- No related articles found.